AU2013216123B2 - Paroxetine derivative - Google Patents

Paroxetine derivative Download PDF

Info

Publication number
AU2013216123B2
AU2013216123B2 AU2013216123A AU2013216123A AU2013216123B2 AU 2013216123 B2 AU2013216123 B2 AU 2013216123B2 AU 2013216123 A AU2013216123 A AU 2013216123A AU 2013216123 A AU2013216123 A AU 2013216123A AU 2013216123 B2 AU2013216123 B2 AU 2013216123B2
Authority
AU
Australia
Prior art keywords
compound
group
acceptable salt
pharmacologically acceptable
paroxetine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013216123A
Other languages
English (en)
Other versions
AU2013216123A1 (en
Inventor
Tomoki Nishioka
Keigo Tanaka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Publication of AU2013216123A1 publication Critical patent/AU2013216123A1/en
Application granted granted Critical
Publication of AU2013216123B2 publication Critical patent/AU2013216123B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2013216123A 2012-01-31 2013-01-29 Paroxetine derivative Ceased AU2013216123B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261592896P 2012-01-31 2012-01-31
US61/592896 2012-01-31
PCT/JP2013/051858 WO2013115163A1 (ja) 2012-01-31 2013-01-29 パロキセチン誘導体

Publications (2)

Publication Number Publication Date
AU2013216123A1 AU2013216123A1 (en) 2014-07-17
AU2013216123B2 true AU2013216123B2 (en) 2016-10-20

Family

ID=48870749

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013216123A Ceased AU2013216123B2 (en) 2012-01-31 2013-01-29 Paroxetine derivative

Country Status (16)

Country Link
US (1) US8933100B2 (enExample)
EP (1) EP2810942B1 (enExample)
JP (1) JP6055784B2 (enExample)
KR (1) KR101950057B1 (enExample)
CN (1) CN104039777B (enExample)
AR (1) AR089837A1 (enExample)
AU (1) AU2013216123B2 (enExample)
BR (1) BR112014016197A8 (enExample)
CA (1) CA2861479C (enExample)
ES (1) ES2576082T3 (enExample)
IL (1) IL233327A (enExample)
IN (1) IN2014CN04922A (enExample)
MX (1) MX355654B (enExample)
RU (1) RU2616610C2 (enExample)
TW (1) TW201334783A (enExample)
WO (1) WO2013115163A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA43313B1 (fr) * 2015-09-02 2022-06-30 Trevena Inc Aza-hétérocyclique à 6 éléments contenant des composés modulateurs de récepteurs opioïdes delta, et leurs procédés de fabrication et d'utilisation
CN110446495B (zh) 2017-02-17 2023-09-05 特维娜有限公司 含有7元氮杂杂环的δ阿片受体调节化合物及其使用和制备方法
CN111533682B (zh) * 2020-05-29 2022-03-01 清华大学 帕罗西汀及其类似物的制备方法
CN116406268A (zh) 2020-10-27 2023-07-07 特维娜有限公司 δ-阿片样物质调节剂的结晶和无定形形式

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007016431A2 (en) * 2005-07-29 2007-02-08 Concert Pharmaceuticals Inc. Novel benzo [d] [1,3]-dioxol derivatives

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1422263A (en) 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
JP2002503248A (ja) 1997-06-10 2002-01-29 シントン・ベスローテン・フェンノートシャップ ４−フェニルピペリジン化合物
IT1308629B1 (it) * 1999-02-23 2002-01-09 Recordati Chem Pharm Processo per la produzione di paroxetina.
US20070142389A1 (en) * 2005-12-20 2007-06-21 Pfizer Inc. Piperidine derivatives
JP2009184924A (ja) 2006-05-31 2009-08-20 Eisai R & D Management Co Ltd 生物学的試薬用化合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007016431A2 (en) * 2005-07-29 2007-02-08 Concert Pharmaceuticals Inc. Novel benzo [d] [1,3]-dioxol derivatives

Also Published As

Publication number Publication date
IL233327A (en) 2016-03-31
KR101950057B1 (ko) 2019-02-19
CA2861479C (en) 2017-10-10
IL233327A0 (en) 2014-08-31
JP6055784B2 (ja) 2016-12-27
CN104039777B (zh) 2016-03-02
AR089837A1 (es) 2014-09-17
EP2810942B1 (en) 2016-03-30
CA2861479A1 (en) 2013-08-08
EP2810942A4 (en) 2015-07-01
CN104039777A (zh) 2014-09-10
ES2576082T3 (es) 2016-07-05
TW201334783A (zh) 2013-09-01
RU2014126321A (ru) 2016-03-20
RU2616610C2 (ru) 2017-04-18
US8933100B2 (en) 2015-01-13
EP2810942A1 (en) 2014-12-10
US20130197033A1 (en) 2013-08-01
MX355654B (es) 2018-04-26
JPWO2013115163A1 (ja) 2015-05-11
KR20140117454A (ko) 2014-10-07
IN2014CN04922A (enExample) 2015-09-18
MX2014007620A (es) 2014-09-15
WO2013115163A1 (ja) 2013-08-08
BR112014016197A8 (pt) 2017-07-04
AU2013216123A1 (en) 2014-07-17
BR112014016197A2 (pt) 2017-06-13

Similar Documents

Publication Publication Date Title
RS61979B1 (sr) N-[4-fluoro-5-[[(2s,4s)-2-metil-4-[(5-metil-1,2,4-oksadiazol-3il)metoksi]-1-piperidil]metil]tiazol-2-il]acetamid kao oga inhibitor
EP2810942B1 (en) Paroxetine derivative
EP2757103B1 (en) Pyrrolidine-3-ylacetic acid derivative
CN115974855A (zh) Ezh2和hdac双靶点抑制剂、其药物组合物及其制备方法和用途
EP2810943B1 (en) Sitaxentan derivative
FR2758329A1 (fr) Derives d'imidazole-4-butane boronique, leur preparation et leur utilisation en therapeutique
WO2013115167A1 (ja) アムバチニブ誘導体
JP2016003186A (ja) フタラン環含有アデノシンａ２ａ受容体拮抗薬
Gaali Design and Synthesis of Selective Ligands for the FK506-binding Protein 51
HK1198034A (en) Pyrrolidine-3-ylacetic acid derivative

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired